New Campaign for Rentschler's 'Facility of the Year'

Laupheim, (PresseBox) - Rentschler, one of the most qualified partners for the development and production of biopharmaceuticals worldwide, has undergone significant expansion in the past years and has transformed itself into a leading contract manufacturer of clinical trial material and for market supply of drug products ranging from low-dose cytokines to higher-dose antibodies and biosimilars. Rentschler is now marking this transformation with a new campaign.

During the past five years, production capacities have been increased. Among other new systems, a 1,000 L multi-product disposable facility has been commissioned that was recently recognized with the prestigious Facility of the Year Award (FOYA) in the category Equipment Innovation. More than 300 new jobs have been created.

Dr. Nikolaus F. Rentschler, CEO and Owner of Rentschler Biotechnologie comments, "We are delighted to have received the FOYA for expanding our manufacturing facilities. It rewards our competence beyond the project business as the new facilities will allow us to cost efficiently design and build dedicated production facilities for our customers to ensure the market supply of their products."

To reflect the company's transformation, Rentschler has launched a new website to coincide with BIO 2012. The new slogan 'Connect. Grow. Succeed.' conveys that by contacting (Connect) and collaborating (Grow) with Rentschler, a successful project outcome (Succeed) will be achieved. Thus, the slogan summarizes the main advantages and benefits for the customer in a nutshell.

Rentschler has a very successful track record spanning more than three decades. Today, the company operates nine independent GMP suites comprising stainless steel bioreactors ranging from 30 L to 2,500 L and two 1,000 L single-use systems.

Rentschler Biotechnologie GmbH

Rentschler Biotechnologie GmbH is a global full-service contract manufacturer with more than 35 years of experience in the development, production and approval of biopharmaceuticals in compliance with international GMP standards (EMA/FDA). Rentschler has nine GMP suites with volumes of 30, 50, 250, 500, 1,000 and 2,500 liters, allowing the production of material for clinical trials (phases I to III) and for market supply and also provides regulatory advice, protein analytics, quality control, and the sterile filling of syringes and injection vials. The company is family-owned and independent and has currently about 650 employees.

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

So beeinflusst Machine Learning die Business Intelligence

In mei­nem Ar­beits­le­ben ha­be ich Bu­si­ness In­tel­li­gen­ce (BI) von bei­den Sei­ten ge­se­hen – als Soft­wa­re­ent­wick­ler und als An­wen­der. So ha­be ich ei­nen Ein­blick in die Her­aus­for­de­run­gen ge­won­nen, mit de­nen die je­wei­li­gen Sei­ten kon­fron­tiert sind – bei der Ent­wick­lung so­wie bei der Nut­zung von BI-Lö­sun­gen.

Weiterlesen

Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.


I want to subscribe to the gratis press mail and have read and accepted the conditions.